Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies

Redefining Precision Management of r/r Large B-Cell Lymphoma: Novel Antibodies Take on CART and BMT in the Quest for Future Treatment Strategies

The treatment paradigms for patients with relapsed large B-cell lymphoma are expanding. Chimeric antigen receptor technology (CAR-T) has revolutionized the management of these patients. Novel bispecific antibodies and antibody–drug conjugates, used as chemotherapy-free single agents or in combinatio...

Full description

Bibliographic Details
Main Author:	Reyad Dada
Format:	Article
Language:	English
Published:	MDPI AG 2023-07-01
Series:	Cells
Subjects:	large B-cell lymphoma LBL CART bispecific antibodies antibody–drug conjugate
Online Access:	https://www.mdpi.com/2073-4409/12/14/1858

Similar Items

Editorial: Novel treatments for diffuse large B-cell lymphoma: The post-CART era
by: Alberto Mussetti, et al.
Published: (2022-08-01)

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
by: Eva González Barca
Published: (2022-07-01)

Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
by: Suheil Albert Atallah-Yunes, et al.
Published: (2022-01-01)

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure
by: Ana Carolina Caballero, et al.
Published: (2022-07-01)

Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.
by: Jérôme Paillassa, et al.
Published: (2022-01-01)

Immunotherapies of retinoblastoma: Effective methods for preserving vision in the future
by: Ling Wang, et al.
Published: (2022-09-01)

Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting
by: Zhijuan Lin, et al.
Published: (2023-04-01)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
by: Lopedote P, et al.
Published: (2023-03-01)

Bispecific antibody drug conjugates: Making 1+1>2
by: Yilin Gu, et al.
Published: (2024-05-01)

The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From Structure to Prospective Clinical Use
by: Rita Tavarozzi, et al.
Published: (2022-02-01)

T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and future directions
by: David A. Russler-Germain, et al.
Published: (2023-07-01)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
by: Neeraj Jain, et al.
Published: (2023-08-01)

Development of combinatorial antibody therapies for diffuse large B cell lymphoma
by: Eric S. Geanes, et al.
Published: (2022-10-01)

A Case of B-Cell Lymphoblastic Lymphoma Presenting with an Isolated Epidural Mass Treated Successfully with Radiotherapy Followed by United Kingdom Acute Lymphoblastic Leukemia (UKALL) Chemotherapy Protocol
by: Musa Fares Alzahrani
Published: (2024-11-01)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
by: Roa Alsajjan, et al.
Published: (2023-09-01)

The landscape of T-cell engagers for the treatment of follicular lymphoma
by: Alfredo Rivas-Delgado, et al.
Published: (2024-12-01)

Advances in Emerging Therapies for Multiple Myeloma
by: QIAN Chenjing, et al.
Published: (2023-03-01)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
by: Gregorio Barilà, et al.
Published: (2021-01-01)

Regulatory considerations in the design, development and quality of monoclonal antibodies and related products for the diagnosis and treatment of cancer
by: Marjorie A. Shapiro
Published: (2024-04-01)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
by: Waqqas Tai, et al.
Published: (2022-03-01)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024-09-01)

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy
by: Tiancheng Zhang, et al.
Published: (2023-03-01)

Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
by: Marilia Barreca, et al.
Published: (2022-12-01)

Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment
by: Valentina Urzì Brancati, et al.
Published: (2023-04-01)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
by: Margaux Lejeune, et al.
Published: (2020-05-01)

Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure
by: Fei Xue, et al.
Published: (2024-06-01)

Cancer Immunotherapy and the Immune Response in Hodgkin Lymphoma
by: Christoph Renner, et al.
Published: (2018-06-01)

Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01)

Identification of mpox M1R and B6R monoclonal and bispecific antibodies that efficiently neutralize authentic mpox virus
by: Zuning Ren, et al.
Published: (2024-12-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

Episomal Vectors for Stable Production of Recombinant Proteins and Engineered Antibodies
by: Ian Fallahee, et al.
Published: (2024-03-01)

Emerging Trends in Immunotherapy for Cancer
by: Alok K. Mishra, et al.
Published: (2022-09-01)

Treatment selection for patients with relapsed or refractory follicular lymphoma
by: Alan Z. Skarbnik, et al.
Published: (2023-03-01)

Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
by: Caitlin Fawcett, et al.
Published: (2024-12-01)

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
by: Charalampos Theocharopoulos, et al.
Published: (2021-09-01)

Cutaneous Lymphoma and Antibody-Directed Therapies
by: Alvise Sernicola, et al.
Published: (2023-03-01)

Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy
by: CHAI Xiaofei, et al.
Published: (2023-03-01)

Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces
by: W. van der Wulp, et al.
Published: (2024-12-01)

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity
by: Alyssa Synan, et al.
Published: (2025-12-01)

The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases
by: Peyton High, et al.
Published: (2024-07-01)